Parkinson's disease

Safety of Plasma Infusions in Parkinson’s Disease

Authors: Jordan E Parker, Amaris Martinez, Gayle K Deutsch, Varsha Prabhakar, Melanie Lising, Kristopher I Kapphahn, Chioma M Anidi, Raumin Neuville, Maria Coburn, Neil Shah, Helen M Bronte-Stewart

Journal: Movement Disorders

Year Published: 2020

Background: Young plasma infusions have emerged as a potential treatment for neurodegenerative disease, and convalescent plasma therapy has been used safely in the management of viral pandemics. However, the effect of plasma therapy in Parkinson’s disease […]

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia

Authors: Claudia Trenkwalder, Daniela Berg, Olivier Rascol, Karla Eggert, Andres Ceballos-Baumann, Jean-Christophe Corvol, Alexander Storch, Lin Zhang, Jean-Philippe Azulay, Emmanuel Broussolle, Luc Defebvre, Christian Geny, Michal Gostkowski, Fabrizio Stocchi, Christine Tranchant, Pascal Derkinderen, Franck Durif, Alberto J Espay, Andrew Feigin, Jean-Luc Houeto, Johannes Schwarz, Thérèse Di Paolo, Dominik Feuerbach, Hans-Ulrich Hockey, Judith Jaeger, Annamaria Jakab, Donald Johns, Gurutz Linazasoro, Paul Maruff, Izabela Rozenberg, Judit Sovago, Markus Weiss, Baltazar Gomez-Mancilla

Journal: Movement Disorders

Year Published: 2016

Background: This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson’s disease and levodopa-induced dyskinesia. Methods: Patients with idiopathic Parkinson’s disease and […]

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

Authors: Fabrizio Stocchi, Olivier Rascol, Alain Destee, Nobutaka Hattori, Robert A Hauser, Anthony E Lang, Werner Poewe, Mark Stacy, Eduardo Tolosa, Haitao Gao, Jennifer Nagel, Martin Merschhemke, Ana Graf, Christopher Kenney, Claudia Trenkwalder

Journal: Movement Disorders

Year Published: 2013

AFQ056 is a novel, selective metabotropic glutamate receptor 5 antagonist. This was a 13-week, double-blind, placebo-controlled study. Patients with Parkinson’s disease and moderate-to-severe levodopa (l-dopa)-induced dyskinesia who were receiving stable l-dopa/anti-parkinsonian treatment and were not currently […]

Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

Authors: Murat Emre, Magda Tsolaki, Ubaldo Bonuccelli, Alain Destée, Eduardo Tolosa, Alexandra Kutzelnigg, Andrés Ceballos-Baumann, Slobodan Zdravkovic, Anna Bladström, Roy Jones, 11018 Study Investigators

Journal: Neurology

Year Published: 2010

Background: Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in […]

Back to Publications